Central nervous system delivery of helper-dependent canine adenovirus corrects neuropathology and behavior in mucopolysaccharidosis type VII mice

Human Gene Therapy

Volumn 25, Issue 3, 2014, Pages 199-211

  Ariza, Lorena ^a   Giménez Llort, Lydia ^b   Cubizolle, Aurélie ^c   Pagès, Gemma ^a   García Lareu, Belén ^a   Serratrice, Nicolas ^c   Cots, Dan ^a   Thwaite, Rosemary ^a   Chillón, Miguel ^a,d   Kremer, Eric J ^c   Bosch, Assumpció ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUT DE NEUROCIÈNCIES   (Spain)

^c INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GLUCURONIDASE; CANINE ADENOVIRUS TYPE 2 VECTOR; GLYCOSAMINOGLYCAN; LYSOSOME ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CANINE ADENOVIRUS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; FOREBRAIN; HISTOPATHOLOGY; LYSOSOME STORAGE DISEASE; MESENCEPHALON; MICROGLIA; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NEUROPATHOLOGY; NONHUMAN; THERAPY;

ADENOVIRUSES, CANINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DOGS; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; GLUCURONIDASE; GLYCOSAMINOGLYCANS; HELPER VIRUSES; IMMUNITY, INNATE; INJECTIONS; LYSOSOMES; MICE; MICROGLIA; MUCOPOLYSACCHARIDOSIS VII; TRANSGENES;

EID: 84896349144     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.152     Document Type: Article

References (51)

1. Birkenmeier, E.H., Davisson, M.T., Beamer, W.G., et al. (1989). Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J. Clin. Invest. 83, 1258-1266.
2. Bosch, A., Perret, E., Desmaris, N., and Heard, J.M. (2000a). Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther. 1, 63-70.
3. Bosch, A., Perret, E., Desmaris, N., et al. (2000b). Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11, 1139-1150.
4. Cao, H., Yang, T., Li, X.F., et al. (2011). Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression. Gene Ther. 18, 173-181.
5. Cardone, M., Polito, V.A., Pepe, S., et al. (2006). Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum. Mol. Genet. 15, 1225-1236.
6. Chen, Y.H., Claflin, K., Geoghegan, J.C., and Davidson, B.L. (2012). Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol. Ther. 20, 1393-1399.
7. Chirmule, N., Propert, K., Magosin, S., et al. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574-1583.
8. Ciron, C., Desmaris, N., Colle, M.A., et al. (2006). Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol. 60, 204-213.
9. Crane, B., Luo, X., Demaster, A., et al. (2012). Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia. Gene Ther. 19, 443-452.
10. Cressant, A., Desmaris, N., Verot, L., et al. (2004). Improved behavior and neuropathology in the mouse model of Sanfi-lippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci. 24, 10229-10239.
11. Dimmock, D., Brunetti-Pierri, N., Palmer, D.J., et al. (2011). Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors. Hum. Gene Ther. 22, 483-488.
12. Dindot, S., Piccolo, P., Grove, N., et al. (2011). Intrathecal injection of helper-dependent adenoviral vectors results in long-term transgene expression in neuroependymal cells and neurons. Hum. Gene Ther. 22, 745-751.
13. Ellinwood, N.M., Ausseil, J., Desmaris, N., et al. (2011). Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol. Ther. 19, 251-259.
14. Eng, C.M., Guffon, N., Wilcox, W.R., et al. (2001). Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 345, 9-16.
15. Gimenez-Llort, L., Fernandez-Teruel, A., Escorihuela, R.M., et al. (2002). Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci. 16, 547-550.
16. Gimenez-Llort, L., Blazquez, G., Canete, T., et al. (2007). Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci. Biobehav. Rev. 31, 125-147.
17. Grabowski, G.A., Leslie, N., and Wenstrup, R. (1998). Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 12, 115-133.
18. Harmatz, P., Giugliani, R., Schwartz, I., et al. (2006). Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 148, 533-539.
19. Kakkis, E.D., Muenzer, J., Tiller, G.E., et al. (2001). Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344, 182-188.
20. Keriel, A., Rene, C., Galer, C., et al. (2006). Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors. J. Virol. 80, 1487-1496.
21. Kremer, E.J., Boutin, S., Chillon, M., and Danos, O. (2000). Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74, 505-512.
22. Langford-Smith, A., Wilkinson, F.L., Langford-Smith, K.J., et al. (2012). Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopoly-saccharidosis IIIA mice. Mol. Ther. 20, 1610-1621.
23. Lau, A.A., Rozaklis, T., Ibanes, S., et al. (2012). Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene 491, 53-57.
24. LeBowitz, J.H., Grubb, J.H., Maga, J.A., et al. (2004). Glyco-sylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc. Natl. Acad. Sci. USA 101, 3083-3088.
25. Levy, B., Galvin, N., Vogler, C., et al. (1996). Neuropathology of murine mucopolysaccharidosis type VII. Acta Neuro-pathol. 92, 562-568.
26. Liu, G., Martins, I., Wemmie, J.A., et al. (2005). Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neu-rosci. 25, 9321-9327.
27. Liu, G., Chen, Y.H., He, X., et al. (2007). Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol. Ther. 15, 242-247.
28. Lowenstein, P.R., Mandel, R.J., Xiong, W.D., et al. (2007). Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of im-munological synapses in understanding the cell biology of neuroimmune interactions. Curr. Gene Ther. 7, 347-360.
29. Moore, D.J., Markmann, J.F., and Deng, S. (2006). Avenues for immunomodulation and graft protection by gene therapy in transplantation. Transpl. Int. 19, 435-445.
30. Muenzer, J. (2011). Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 50 Suppl. 5, v4-v12.
31. Muhammad, A.K., Xiong, W., Puntel, M., et al. (2012). Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Hum. Gene Ther. Methods 23, 271-284.
32. O'Connor, L.H., Erway, L.C., Vogler, C.A., et al. (1998). Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J. Clin. Invest. 101, 1394-1400.
33. Perreau, M., and Kremer, E.J. (2005). Frequency, proliferation, and activation of human memory T cells induced by a non-human adenovirus. J. Virol. 79, 14595-14605.
34. Perreau, M., Guerin, M.C., Drouet, C., and Kremer, E.J. (2007a). Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer. Mol. Ther. 15, 1998-2007.
35. Perreau, M., Mennechet, F., Serratrice, N., et al. (2007b). Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J. Virol. 81, 3272-3284.
36. Salinas, S., Bilsland, L.G., Henaff, D., et al. (2009). CAR-associated vesicular transport of an adenovirus in motor neuron axons. PLoS Pathog. 5, e1000442.
37. Sardiello, M., Palmieri, M., di Ronza, A., et al. (2009). A gene network regulating lysosomal biogenesis and function. Science 325, 473-477.
38. Schagen, F.H., Rademaker, H.J., Rabelink, M.J., et al. (2000). Ammonium sulphate precipitation of recombinant adenovirus from culture medium: an easy method to increase the total virus yield. Gene Ther. 7, 1570-1574.
39. Schuldt, A.J., Hampton, T.J., Chu, V., et al. (2004). Electrocardio-graphic and other cardiac anomalies in beta-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation. Proc. Natl. Acad. Sci. USA 101, 603-608.
40. Seok, J., Warren, H.S., Cuenca, A.G., et al. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA 110, 3507-3512.
41. Shipley, J.M., Klinkenberg, M., Wu, B.M., et al. (1993). Mu-tational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes. Am. J. Hum. Genet. 52, 517-526.
42. Sly, W.S., Vogler, C., Grubb, J.H., et al. (2001). Active site mutant transgene confers tolerance to human beta-glucuron-idase without affecting the phenotype of MPS VII mice. Proc. Natl. Acad. Sci. USA 98, 2205-2210.
43. Soper, B.W., Lessard, M.D., Vogler, C.A., et al. (2001). Non-ablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency. Blood 97, 1498-1504.
44. Sotak, B.N., Hnasko, T.S., Robinson, S., et al. (2005). Dysre-gulation of dopamine signaling in the dorsal striatum inhibits feeding. Brain Res. 1061, 88-96.
45. Soudais, C., Laplace-Builhe, C., Kissa, K., and Kremer, E.J. (2001). Preferential transduction of neurons by canine ade-novirus vectors and their efficient retrograde transport in vivo. FASEB J. 15, 2283-2285.
46. Soudais, C., Skander, N., and Kremer, E.J. (2004). Long-term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. FASEB J. 18, 391-393.
47. Thomas, C.E., Birkett, D., Anozie, I., et al. (2001). Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol. Ther. 3, 36-46.
48. Thurberg, B.L., Lynch Maloney, C., Vaccaro, C., et al. (2006). Characterization of pre-and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab. Invest. 86, 1208-1220.
49. Vogler, C., Levy, B., Kyle, J.W., et al. (1994). Mucopoly-saccharidosis VII: postmortem biochemical and pathological findings in a young adult with beta-glucuronidase deficiency. Mod. Pathol. 7, 132-137.
50. Vogler, C., Sands, M.S., Galvin, N., et al. (1998). Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of ly-sosomal storage disease. J. Inherit. Metab. Dis. 21, 575-586.
51. Wilcox, W.R., Banikazemi, M., Guffon, N., et al. (2004). Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75, 65-74.